Danaher (DHR) March 125 calls active after acquiring the biopharma business of GE Life Sciences
Tweet
Share
E-mail
Get Alerts DHR Hot Sheet
Price: $227.53 +1.35%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 0.7%
Revenue Growth %: +8.3%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 0.7%
Revenue Growth %: +8.3%
Join SI Premium – FREE
Danaher (NYSE: DHR) March call option implied volatility is at 18, April is at 16; compared to its 52-week range of 14 to 37 after announcing that it has entered into a definitive agreement with General Electric (GE) to acquire the biopharma business of GE Life Sciences for a cash purchase price of approximately $21.4B. Call put ratio 5.3 calls to 1 put with focus on March 125.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vail Resorts (MTN) 2200 contracts October 145 puts trade into quarter results
- Portland General Electric halts holding company restructuring plan
- Gladstone Investment backs Detroit Defense merger with Athenix
Create E-mail Alert Related Categories
OptionsRelated Entities
Options, Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
